Phospholipase A2 activity in first episode schizophrenia: Associations with symptom severity and outcome at week 12

World Journal of Biological Psychiatry

Volumn 12, Issue 8, 2011, Pages 598-607

  Smesny, Stefan ^a   Kunstmann, Christina ^a   Kunstmann, Sebastian ^a   Willhardt, Ingo ^b   Lasch, Juergen ^b   Yotter, Rachel A ^a   Proffitt, Tina Marie ^c   Kerr, Melissa ^c   Marculev, Conny ^c   Milleit, Berko ^a   Milleit, Christine ^a   Nenadic, Igor ^a   Amminger, Paul ^c   McGorry, Patrick D ^c   Sauer, Heinrich ^a   Berger, Gregor E ^d  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Integrated Psychiatry Winterthur IPW   (Switzerland)

Author keywords

Functional impairment; Longitudinal; Negative symptoms; Phospholipase A2; Schizophrenia

Indexed keywords

BENZODIAZEPINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHOLIPASE A2; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; ENZYME ACTIVITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; TREATMENT RESPONSE; ADOLESCENT; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; HOSPITALIZATION; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; PHOSPHOLIPASES A2; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82955217320     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.541283     Document Type: Article

References (38)

1. Andreasen NC. 1983. The Scale for the Assessment of Negative Symptoms. Iowa, USA: The University of Iowa.
2. 2. Annu Rev Pharmacol Toxicol 39:175-189. (Pubitemid 29222556)
3. Dennis EA. 1994. Diversity of group types, regulation, and function of phospholipase A 2. J Biol Chem 269:13057-13060. (Pubitemid 24206060)
4. Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T. 1999. Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. Am J Psychiatry 156:1205-1208. (Pubitemid 29374880)
5. 2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry 22:421-426. (Pubitemid 17041622)
6. 2 activity in schizophrenia: a replication study. Biol Psychiatry 28:495-501. (Pubitemid 20298440)
7. 2 activity in schizophrenia. Schizophr Res 16:1-6.
8. Goldman HH, Skodol AE, Lave TR. 1992. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 149:1148-1156.
9. Hafner H, Van der Heiden W, Behrens S, Gattaz WF, Hambrecht M, Loffl er W, et al. 1998. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr Bull 24:99-113. (Pubitemid 28128492)
10. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. 1991. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 30:795-805.
11. 2beta-implications for structure and function. J Biol Chem 276:7129-7135.
12. Jones SH, Thornicroft G, Coffey M, Dunn G. 1995. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166:654-659.
13. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276. (Pubitemid 18039085)
14. 2 activity with three different substrates in biological samples of patients with schizophrenia. Clin Chem Lab Med 41:908-914. (Pubitemid 37010184)
15. 2 in schizophrenia. Mol Psychiatry 11:547-556.
16. 2. Br J Pharmacol 144:940-952. (Pubitemid 40593020)
17. 2 using ELISA. Prostaglandins Leukot Essent Fatty Acids 70:377-381. (Pubitemid 38429271)
18. 2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 34:641-649.
19. Overall JE, Gorham DR. 1962. The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
20. Pangerl AM, Steudle A, Jaroni HW, Rufer R, Gattaz WF. 1991. Increased platelet membrane lysophosphatidylcholine in schizophrenia. Biol Psychiatry 30:837-840.
21. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, et al. 1991. Alterations in brain highenergy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 48:563-568.
22. 2. Arch Gen Psychiatry 54:487-494. (Pubitemid 27198211)
23. 2 activities in brain of patients with schizophrenia. Brain Res 821:407-413. (Pubitemid 29222805)
24. Shioiri T, Kato T, Inubushi T, Murashita J, Takahashi S. 1994. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res 55:223-235.
25. Smesny S, Kinder D, Willhardt I, Rosburg T, Lasch J, Berger G, et al. 2005. Increased calcium-independent phospholipase A 2 activity in first but not in multi-episode chronic schizophrenia. Biol Psychiatry 57:399-405. (Pubitemid 40215770)
26. 2 Activity in CSF of patients with Dementia. J Neural Transm 115:1173-9.
27. 2 by generating a diffusible bromomethyl keto acid that alkylates cysteine thiols. Biochemistry 45:1061-1073. (Pubitemid 43124112)
28. Spitzer RL, Williams JB, Gibbon M, First MB. 1990. Structured Clinical Interview for DSM-III-R? Patient Edition (SCID-P, version 1.0). Washington, DC: American Psychiatric Press.
29. Sun GY, Xu J, Jensen MD, Simonyi A. 2004. Phospholipase A 2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 45:205-213. (Pubitemid 38228817)
30. Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson M, Eiser A, et al. 2000. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 45:191-201.
31. 2 activity in schizophrenia with absent response to niacin. Schizophr Res 61:1-6. (Pubitemid 36335816)
32. 31P magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics with a volume selective technique-preliminary findings. Biol Psychiatry 41:644-648. (Pubitemid 27157755)
33. 31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics-a study including 50 patients and 36 controls. Biol Psychiatry 44:399-404. (Pubitemid 28451924)
34. 31P chemical shift spectroscopic-imaging study. Biol Psychiatry 47:954-961. (Pubitemid 30320740)
35. 2 leads to neutrophil recruitment to coronary artery endothelial cells. Thromb Res 120:597-605. (Pubitemid 47094909)
36. 31P-spectroscopy of frontal lobe in schizophrenia: alterations in phospholipid and high-energy phosphate metabolism. Schizophr Res 58:117-122. (Pubitemid 35284503)
37. Yao JK, Leonard S, Reddy RD. 2000a. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42:7-17. (Pubitemid 30116755)
38. 31P MRS brain measures in schizophrenia. Soc Biol Psychiatry 47:41.